Lifeway Foods, Inc. provided additional information on November 26, 2024, regarding its Board of Directors' decision to reject Danone North America PBC's revised unsolicited proposal of $27.00 per share. The Board reiterated its determination that the offer substantially undervalues the Company.
The Board affirmed it is not opposed to a sale of the Company at a price that accurately reflects its true value. It emphasized its belief that Lifeway's standalone plan has strong potential to provide superior value to all shareholders, driven by double-digit growth and anticipated margin expansion.
Lifeway Foods is targeting Adjusted EBITDA of between $45 million and $50 million in fiscal year 2027. This outlook is based on the company's sustained momentum, increasing consumer recognition of gut microbiome importance, and the benefits of its protein and probiotic-rich kefir products.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.